MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Early screening for geographic atrophy may help slow progression to foveal involvement. Collaborating with optometrists on geographic atrophy care is beneficial for patients. Healio spoke with Yasha S ...
Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
September 2, 2008 — A gene variant that protects against geographic atrophy has been identified by investigators from several institutions in China and the United States. The variant appears to ...
Avacincaptad pegol (Zimura, IVERIC bio) slows the progression of geographic atrophy, results from a phase 3 clinical trial show, giving hope that there will soon be an approved treatment for one of ...
Maybe you’ve noticed that you can no longer see your friends and family clearly. Or perhaps it’s becoming increasingly hard — if not impossible — to drive yourself to your favorite restaurant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback